Company news
Spyre Therapeutics, Inc. (NASDAQ:SYRE) news
Spyre Therapeutics, Inc. news releases on 6ix. Latest, Oct 5, 2026: Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Press releases & updates
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
October 5, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
October 4, 2026
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
October 4, 2026
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
October 4, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
October 2, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
October 1, 2026
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
September 8, 2026
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
September 3, 2026
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
August 25, 2026
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
August 10, 2026
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
June 14, 2026
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
June 3, 2026
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 5, 2026
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
April 15, 2026
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
April 13, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
April 12, 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
April 12, 2026
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
April 9, 2026
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
March 15, 2026
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 19, 2026
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
February 18, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
February 6, 2026
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
January 11, 2026
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 3, 2025
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
November 3, 2025
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
October 28, 2025
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
October 23, 2025
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
October 14, 2025
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
October 12, 2025
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 4, 2025
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
September 14, 2025
Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
September 8, 2025
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 5, 2025
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
June 16, 2025
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
June 15, 2025
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
May 27, 2025
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 7, 2025
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
May 4, 2025
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
March 26, 2025
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 26, 2025
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2025
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
February 18, 2025
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
January 12, 2025
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
December 17, 2024
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
December 1, 2024
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 24, 2024
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
November 17, 2024
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
November 17, 2024
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potenti...
November 11, 2024